The latest data point for NVO's net income in Q4'25 shows $26.89B USD, reflecting a slight decline from the previous quarter's $20.01B USD but remaining above the annual average. This figure represents a year-over-year decrease of -4.74%, indicating moderated growth compared to earlier periods in 2025. Over the period from Q1'23 to Q4'25, net income has exhibited an overall upward trend, rising from $19.81B USD to a peak of $29.03B USD in Q1'25, with notable volatility including a dip to $20.05B USD in Q2'24 and a sharp YoY contraction of -26.72% in Q3'25. Year-over-year growth started strong at 39.44% in Q1'23, peaking at 61.59% in Q4'23, before decelerating and turning negative in late 2025, suggesting potential headwinds in profitability despite the long-term expansion driven by the pharmaceutical sector's demand. The bar chart visualization highlights quarterly fluctuations, while the overlaid YoY line underscores shifting momentum.